AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast...

por Mu, Zhaomei, Klinowska, Teresa, Dong, Xiaoshen, Foster, Emily, Womack, Chris, Fernandez, Sandra V, Cristofanilli, Massimo
Publicado 2014

HO-1 drives autophagy as a mechanism of resistance against HER2-targeted therapies

por Tracey, Natasha, Creedon, Helen, Kemp, Alain J., Culley, Jayne, Muir, Morwenna, Klinowska, Teresa, Brunton, Valerie G.
Publicado 2019

Combining AZD8931, a novel EGFR/HER2/HER3 signalling inhibitor, with AZD5363 limits AKT inhibitor induced feedback and enhances antitumour efficacy in HER2-amplified breast cancer...

por CRAFTER, CLAIRE, VINCENT, JOHN P., TANG, ERIC, DUDLEY, PHILLIPPA, JAMES, NEIL H., KLINOWSKA, TERESA, DAVIES, BARRY R.
Publicado 2015

Use of a genetically engineered mouse model as a preclinical tool for HER2 breast cancer

por Creedon, Helen, Balderstone, Lucy A., Muir, Morwenna, Balla, Jozef, Gomez-Cuadrado, Laura, Tracey, Natasha, Loane, Joseph, Klinowska, Teresa, Muller, William J., Brunton, Valerie G.
Publicado 2016

Overcoming mTOR Resistance Mutations with a New Generation mTOR Inhibitor

por Rodrik-Outmezguine, Vanessa S., Okaniwa, Masanori, Yao, Zhan, Novotny, Chris J., McWhirter, Claire, Banaji, Arpitha, Won, Helen, Wong, Wai, Berger, Mike, de Stanchina, Elisa, Barratt, Derek G., Cosulich, Sabina, Klinowska, Teresa, Rosen, Neal, Shokat, Kevan M.
Publicado 2016

Identification of novel pathways linking epithelial-to-mesenchymal transition with resistance to HER2-targeted therapy

por Creedon, Helen, Gómez-Cuadrado, Laura, Tarnauskaitė, Žygimantė, Balla, Jozef, Canel, Marta, MacLeod, Kenneth G., Serrels, Bryan, Fraser, Craig, Unciti-Broceta, Asier, Tracey, Natasha, Le Bihan, Thierry, Klinowska, Teresa, Sims, Andrew H., Byron, Adam, Brunton, Valerie G.
Publicado 2016

A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors

por Choudhury, Atish D., Higano, Celestia S., de Bono, Johann S., Cook, Natalie, Rathkopf, Dana E., Wisinski, Kari B., Martin-Liberal, Juan, Linch, Mark, Heath, Elisabeth I., Baird, Richard D., García-Carbacho, Javier, Quintela-Fandino, Miguel, Barry, Simon T., de Bruin, Elza C., Colebrook, Steve, Hawkins, George, Klinowska, Teresa, Maroj, Brijesh, Moorthy, Ganesh, Mortimer, Peter G., Moschetta, Michele, Nikolaou, Myria, Sainsbury, Liz, Shapiro, Geoffrey I., Siu, Lillian L., Hansen, Aaron R.
Publicado 2022

Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-a...

por Fu, Xiaoyong, Creighton, Chad J, Biswal, Nrusingh C, Kumar, Vijetha, Shea, Martin, Herrera, Sabrina, Contreras, Alejandro, Gutierrez, Carolina, Wang, Tao, Nanda, Sarmistha, Giuliano, Mario, Morrison, Gladys, Nardone, Agostina, Karlin, Kristen L, Westbrook, Thomas F, Heiser, Laura M, Anur, Pavana, Spellman, Paul, Guichard, Sylvie M, Smith, Paul D, Davies, Barry R, Klinowska, Teresa, Lee, Adrian V, Mills, Gordon B, Rimawi, Mothaffar F, Hilsenbeck, Susan G, Gray, Joe W, Joshi, Amit, Osborne, C Kent, Schiff, Rachel
Publicado 2014

Serial monitoring of genomic alterations in circulating tumor cells of ER‐positive/HER2‐negative advanced breast cancer: feasibility of precision oncology biomarker detection

por Cani, Andi K., Dolce, Emily M., Darga, Elizabeth P., Hu, Kevin, Liu, Chia‐Jen, Pierce, Jackie, Bradbury, Kieran, Kilgour, Elaine, Aung, Kimberly, Schiavon, Gaia, Carroll, Danielle, Carr, T. Hedley, Klinowska, Teresa, Lindemann, Justin, Marshall, Gayle, Rowlands, Vicky, Harrington, Elizabeth A., Barrett, J. Carl, Sathiyayogan, Nitharsan, Morrow, Christopher, Sero, Valeria, Armstrong, Anne C., Baird, Richard, Hamilton, Erika, Im, Seock‐Ah, Jhaveri, Komal, Patel, Manish R., Dive, Caroline, Tomlins, Scott A., Udager, Aaron M., Hayes, Daniel F., Paoletti, Costanza
Publicado 2021

The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER(+) Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance

por Lawson, Mandy, Cureton, Natalie, Ros, Susana, Cheraghchi-Bashi, Azadeh, Urosevic, Jelena, D'Arcy, Sophie, Delpuech, Oona, DuPont, Michelle, Fisher, David I., Gangl, Eric T., Lewis, Hilary, Trueman, Dawn, Wali, Neha, Williamson, Stuart C., Moss, Jennifer, Montaudon, Elodie, Derrien, Heloise, Marangoni, Elisabetta, Miragaia, Ricardo J., Gagrica, Sladjana, Morentin-Gutierrez, Pablo, Moss, Thomas A., Maglennon, Gareth, Sutton, Daniel, Polanski, Radoslaw, Rosen, Alan, Cairns, Jonathan, Zhang, Pei, Sánchez-Guixé, Mònica, Serra, Violeta, Critchlow, Susan E., Scott, James S., Lindemann, Justin P.O., Barry, Simon T., Klinowska, Teresa, Morrow, Christopher J., S Carnevalli, Larissa
Publicado 2023